Back to top

Sareum Completes Key Toxicology Milestone for Autoimmune Drug Candidate SDC-1801

Sareum Holdings ( ($GB:SAR) ) has shared an update. Sareum Holdings has completed dosing in its Phase 2-enabling toxicology programme for SDC-1801,...

Read full article here »

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

Saratoga Investment Corp (SAR)